Profitelligence Profitelligence · Filing Ledger Open GH research →

Form 8-K · Current Report · Filed 2024-06-14

Guardant Health Announces Results of Annual Meeting

On June 12, 2024, Guardant Health, Inc. held its annual meeting of stockholders where all director nominees were elected, the ratification of Deloitte & Touche LLP as the independent public accounting firm was approved, and the advisory vote on executive compensation was not approved.

Filer
Guardant Health Inc. GH · NASDAQ
Filed
Accession
0001193125-24-161223
CIK
0001576280
Signal
Medium impactHealthcare

Items reported

Item 5.07

Submission of Matters to a Vote of Security Holders

Director Elections Results Equity Plan Approved Say-on-Pay Failed

Market reaction

Close before filing

$31.51

Next session

-3.2%

Since filing

+414.1%

Latest close

$161.99

What happened, not what will happen — closing prices around the filing date.

About Guardant Health Inc.

Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.

Exchange NASDAQ Industry Diagnostics & Research Company website ↗

Never miss another GH filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts